水產養殖疫苗市場機會、成長要素、產業趨勢分析及2026年至2035年預測。

2025 年全球水產養殖疫苗市場價值為 4.346 億美元，預計到 2035 年將達到 9.429 億美元，年複合成長率為 8.2%。

全球水產養殖生產的擴張和魚類需求的成長推動了市場成長。細菌和病毒感染疾病弧菌、氣單胞菌和其他病原體引起的感染）的日益頻繁，使得降低死亡率和提高生產力的感染疾病需求不斷成長。水產養殖疫苗是一種能夠刺激魚類和甲殼類動物等水生動物免疫系統的生物製藥，使其對特定病原體產生抵抗力。這些疫苗可透過注射、浸泡或口服給藥，有助於最大限度地減少疾病爆發、減少抗生素的使用並促進永續水產養殖。新興市場，特別是亞太地區和拉丁美洲的市場，以及對口服和浸泡疫苗給藥技術研發投入的增加，都在推動市場成長。製造商和水產養殖公司之間的合作，正在促進創新解決方案的快速商業化和廣泛推廣。

去活化疫苗市場佔有率佔74.3%，預計到2035年將以8.1%的複合年成長率成長。其安全性高、保護範圍廣、穩定性佳，深受養殖者青睞。這類疫苗廣泛應用於各種水產養殖物種，能夠提供穩定的免疫反應，且無復發風險。多種給藥方式，例如注射和浸泡，為養殖戶提供了操作柔軟性。監管標準推薦使用非活病毒疫苗製劑、消費者對無抗生素水產品的需求不斷成長，以及集約化水產養殖系統對生物安全的日益重視，都進一步推動了去活化疫苗的普及應用。

預計到2025年，注射疫苗市場規模將達到2.638億美元，並將以8.1%的複合年成長率持續成長至2035年。注射疫苗透過直接向魚類注射精確劑量，提供卓越的療效和持久的免疫力，確保對細菌和病毒病原體的最佳保護。自動化疫苗接種系統和符合人體工學設計的設備的創新，簡化了接種流程，減輕了動物的壓力反應，並提高了孵化場和養殖場的運作效率。

預計到2025年，歐洲水產養殖疫苗市場佔有率將達到43%，這主要得益於先進的水產養殖產業、對疾病預防法規的高度重視以及疫苗接種計劃的早期實施。對預防性抗生素使用的監管限制正在加速向疫苗的轉變，而完善的低溫運輸分銷網路、專業的獸醫支持以及領先疫苗生產商的存在，都為市場的永續成長做出了貢獻。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 細菌和性行為感染正在增加。
    • 全球水產養殖產量增加
    • 研發並推出一種用於水產養殖的新疫苗
    • 擴大水產養殖疫苗的使用，以取代抗生素
  • 產業潛在風險與挑戰
    • 小規模水產養殖戶意識薄弱
    • 複雜的疫苗研發流程
  • 市場機遇
    • 口服疫苗和浸泡疫苗的出現
    • 新興市場對水產養殖的投資正在增加。
• 成長潛力分析
• 科技趨勢
  • 當前技術趨勢
  • 新興技術
• 監管環境
  • 北美洲
  • 歐洲
  • 亞太地區
• 管道分析
• 未來市場趨勢
• 波特的分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
• 公司矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 擴張計劃

第5章 市場估計與預測：依疫苗類型分類，2022-2035年

• 去活化疫苗
• 減毒活病毒疫苗
• 次單位疫苗
• 其他疫苗類型

第6章 市場估計與預測：依給藥途徑分類，2022-2035年

• 注射疫苗
• 口服疫苗
• 浸沒和噴淋

第7章 市場估計與預測：依應用領域分類，2022-2035年

• 細菌
• 病毒性的
• 寄生蟲
• 合成的

第8章 市場估算與預測：依類型分類，2022-2035年

• 鮭魚
• 鱒魚
• 吳郭魚
• 鈴木
• 海鯛
• 比目魚
• 鯉魚
• 其他魚類

第9章 市場估價與預測：依通路分類，2022-2035年

• 零售
• 電子商務
• 獸醫醫院/獸醫診所附設藥房

第10章 市場估價與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 挪威
  • 愛爾蘭
  • 土耳其
  • 丹麥
• 亞太地區
  • 中國
  • 印度
  • 印尼
  • 菲律賓
  • 越南
  • 澳洲
  • 紐西蘭
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 智利
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第11章：公司簡介

• Cavac
• CIBA
• HIPRA
• Kemin Industries
• Kyoritsu Seiyaku
• Kyoto Biken Laboratories
• Merck Animal Health
• Nisseiken
• Phibro Animal Health
• Tecnovax
• Vaxxinova International
• Veterquimica
• Virbac
• Zoetis

The Global Aquaculture Vaccines Market was valued at USD 434.6 million in 2025 and is estimated to grow at a CAGR of 8.2% to reach USD 942.9 million by 2035.

Market growth is driven by the expansion of global aquaculture production and the rising demand for fish. Frequent bacterial and viral outbreaks, including infections caused by Vibrio, Aeromonas, and other pathogens, have increased the need for vaccines that reduce mortality and improve productivity. Aquaculture vaccines are biological preparations that stimulate the immune system of aquatic animals, such as fish and crustaceans, providing resistance to specific pathogens. Administered via injection, immersion, or oral routes, these vaccines help minimize disease outbreaks, reduce antibiotic use, and promote sustainable fish farming. Emerging markets, particularly in Asia-Pacific and Latin America, are contributing to growth, alongside rising investments in R&D for oral and immersion vaccine delivery. Collaborations between manufacturers and aquaculture companies are enabling faster commercialization and broader access to innovative solutions.

The inactivated vaccines segment held a 74.3% share and is expected to grow at a CAGR of 8.1% through 2035. Their safety profile, broad-spectrum protection, and stability make them highly preferred among producers. These vaccines are widely used across various aquaculture species and provide consistent immune responses without the risk of reverting to virulence. They are available in multiple delivery formats, including injectable and immersion, offering operational flexibility. Regulatory standards favoring non-live formulations, increasing consumer demand for antibiotic-free seafood, and a focus on biosecurity in intensive farming systems further support their adoption.

The injection vaccines segment accounted for USD 263.8 million in 2025 and is projected to grow at a CAGR of 8.1% through 2035. Injectable vaccines offer superior efficacy and long-lasting immunity by delivering precise doses directly to fish, ensuring optimal protection against bacterial and viral pathogens. Innovations in automated vaccination systems and ergonomic devices have simplified administration, reduced stress on animals, and increased operational efficiency across hatcheries and grow-out farms.

Europe Aquaculture Vaccines Market held a 43% share in 2025, driven by its advanced aquaculture industry, strong regulatory emphasis on disease prevention, and early adoption of vaccination programs. Regulatory restrictions on prophylactic antibiotic use have accelerated the shift toward vaccines, while a well-established cold-chain distribution network, skilled veterinary support, and the presence of leading vaccine manufacturers contribute to sustained growth.

Key players in the Global Aquaculture Vaccines Market include Cavac, CIBA, HIPRA, Kemin Industries, Kyoritsu Seiyaku, Kyoto Biken Laboratories, Merck Animal Health, Nisseiken, Phibro Animal Health, Tecnovax, Vaxxinova International, Veterquimica, Virbac, Zoetis. Companies in the Global Aquaculture Vaccines Market are strengthening their positions by investing in research and development of oral and immersion-based delivery systems, expanding manufacturing capacity, and forming strategic alliances with aquaculture operators for faster commercialization. They are also focusing on emerging markets, enhancing cold-chain logistics, offering value-added services such as technical support and training, and ensuring regulatory compliance to build trust and maintain market leadership.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Vaccine type trends
  • 2.2.3 Route of administration trends
  • 2.2.4 Application trends
  • 2.2.5 Species trends
  • 2.2.6 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Surging prevalence of bacterial and viral infections
    • 3.2.1.2 Increasing aquaculture production across the globe
    • 3.2.1.3 Development and launch of new aquaculture vaccines
    • 3.2.1.4 Rising adoption of aquaculture vaccines over antibiotics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Limited awareness among small-scale farmers
    • 3.2.2.2 Complex vaccine development procedures
  • 3.2.3 Market opportunities
    • 3.2.3.1 Emergence of oral and immersion-based vaccines
    • 3.2.3.2 Expansion into emerging markets with rising aquaculture investments
• 3.3 Growth potential analysis
• 3.4 Technology landscape
  • 3.4.1 Current technological trends
  • 3.4.2 Emerging technologies
• 3.5 Regulatory landscape
  • 3.5.1 North America
  • 3.5.2 Europe
  • 3.5.3 Asia Pacific
• 3.6 Pipeline analysis
• 3.7 Future market trends
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Inactivated vaccine
• 5.3 Live attenuated vaccine
• 5.4 Subunit vaccine
• 5.5 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Injection vaccines
• 6.3 Oral vaccines
• 6.4 Immersion and spray

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Bacterial
• 7.3 Viral
• 7.4 Parasitic
• 7.5 Combined

Chapter 8 Market Estimates and Forecast, By Species, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Salmon
• 8.3 Trout
• 8.4 Tilapia
• 8.5 Seabass
• 8.6 Seabream
• 8.7 Turbot
• 8.8 Carp
• 8.9 Other species

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Retail
• 9.3 E-commerce
• 9.4 Veterinary hospital/clinic pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Norway
  • 10.3.7 Ireland
  • 10.3.8 Turkey
  • 10.3.9 Denmark
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Indonesia
  • 10.4.4 Philippines
  • 10.4.5 Vietnam
  • 10.4.6 Australia
  • 10.4.7 New Zealand
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Chile
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Cavac
• 11.2 CIBA
• 11.3 HIPRA
• 11.4 Kemin Industries
• 11.5 Kyoritsu Seiyaku
• 11.6 Kyoto Biken Laboratories
• 11.7 Merck Animal Health
• 11.8 Nisseiken
• 11.9 Phibro Animal Health
• 11.10 Tecnovax
• 11.11 Vaxxinova International
• 11.12 Veterquimica
• 11.13 Virbac
• 11.14 Zoetis